CD19 and myasthenia gravis: Clinical trials are now actively investigating the efficacy of B cell targeting CD19 and B cell maturation antigen (BCMA) CAR T cells across a spectrum of autoimmune diseases, including systemic lupus erythematosus, myositis, pemphigus, multiple sclerosis, myasthenia gravis, and systemic sclerosis, with preliminary results indicating significant therapeutic gains (Table 1).